1
|
Engin AB, Engin ED, Engin A. Targeted Nano-Based Systems for the Anti-Obesity Agent's Delivery. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2024; 1460:657-676. [PMID: 39287868 DOI: 10.1007/978-3-031-63657-8_22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/19/2024]
Abstract
Obesity is a global health concern and a chronic disease that is accompanied by excessive fat storage in adipose and nonadipose tissues. An increase in the body-mass index (BMI) is directly proportional to the 2- to 3.9-fold increase in all-cause mortality in obesity. If left untreated for a longer period, obesity-related metabolic, cardiovascular, inflammatory, and malignant diseases reduce life expectancy. Currently, most of the anti-obesity drugs have failed and fallen into disrepute, either due to their ineffectiveness or adverse effects. In this review, depending on their enhanced pharmacokinetic and biodistribution profiles, whether nanocarriers alter the basic properties and bioactivity of anti-obesity drugs used in clinical practice are debated. First, nanocarriers can improve the safety of still-used anti-obesity drugs by lowering their systemic toxicity through increasing targeting efficacy and preventing drug carrier toxicity. Second, when the micro-ribonucleic acids (miRNAs), which are aberrantly expressed in obesity and obesity-related diseases, are encapsulated into nanoparticles, they are effective in multiple obesity-related metabolic pathways and gene networks. Finally, a synergistic anti-obesity effect with low dose and low toxicity can be obtained with the combinatory therapy applied by encapsulating the anti-obesity drug and gene in the same nanocarrier delivery vehicle.
Collapse
Affiliation(s)
- Ayse Basak Engin
- Faculty of Pharmacy, Department of Toxicology, Gazi University, Hipodrom, Ankara, Turkey.
| | - Evren Doruk Engin
- Biotechnology Institute, Ankara University, Gumusdere, Ankara, Turkey
| | - Atilla Engin
- Faculty of Medicine, Department of General Surgery, Gazi University, Besevler, Ankara, Turkey
- Mustafa Kemal Mah. 2137. Sok. 8/14, 06520, Cankaya, Ankara, Turkey
| |
Collapse
|
2
|
Møller A, Schultz HB, Meola TR, Joyce P, Müllertz A, Prestidge CA. The Influence of Blonanserin Supersaturation in Liquid and Silica Stabilised Self-Nanoemulsifying Drug Delivery Systems on In Vitro Solubilisation. Pharmaceutics 2023; 15:pharmaceutics15010284. [PMID: 36678919 PMCID: PMC9864080 DOI: 10.3390/pharmaceutics15010284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2022] [Revised: 01/09/2023] [Accepted: 01/11/2023] [Indexed: 01/18/2023] Open
Abstract
Reformulating poorly water-soluble drugs as supersaturated lipid-based formulations achieves higher drug loading and potentially improves solubilisation and bioavailability. However, for the weak base blonanserin, silica solidified supersaturated lipid-based formulations have demonstrated reduced in vitro solubilisation compared to their liquid-state counterparts. Therefore, this study aimed to understand the influence of supersaturated drug load on blonanserin solubilisation from liquid and silica solidified supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS) during in vitro lipolysis. Stable liquid super-SNEDDS with varying drug loads (90-300% of the equilibrium solubility) were solidified by imbibition into porous silica microparticles (1:1 lipid: silica ratio). In vitro lipolysis revealed greater blonanserin solubilisation from liquid super-SNEDDS compared to solid at equivalent drug saturation levels, owing to strong silica-BLON/lipid interactions, evidenced by a significant decrease in blonanserin solubilisation upon addition of silica to a digesting liquid super-SNEDDS. An increase in solid super-SNEDDS drug loading led to increased solubilisation, owing to the increased drug:silica and drug:lipid ratios. Solidifying SNEDDS with silica enables the fabrication of powdered formulations with higher blonanserin loading and greater stability than liquid super-SNEDDS, however at the expense of drug solubilisation. These competing parameters need careful consideration in designing optimal super-SNEDDS for pre-clinical and clinical application.
Collapse
Affiliation(s)
- Amalie Møller
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide, SA 5000, Australia
- Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, 2100 Copenhagen, Denmark
- Future Industries Institute, UniSA STEM, Mawson Lakes Campus, University of South Australia, Mawson Lakes, SA 5095, Australia
| | - Hayley B. Schultz
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide, SA 5000, Australia
| | - Tahlia R. Meola
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide, SA 5000, Australia
| | - Paul Joyce
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide, SA 5000, Australia
| | - Anette Müllertz
- Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, 2100 Copenhagen, Denmark
- Bioneer:FARMA, Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, 2100 Copenhagen, Denmark
| | - Clive A. Prestidge
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide, SA 5000, Australia
- Correspondence: ; Tel.: +61-8-830-22438
| |
Collapse
|
3
|
Almasri R, Schultz HB, Møller A, Bremmell KE, Garcia-Bennett A, Joyce P, Prestidge CA. Role of Silica Intrawall Microporosity on Abiraterone Acetate Solubilization and In Vivo Oral Absorption. Mol Pharm 2022; 19:1091-1103. [PMID: 35238208 DOI: 10.1021/acs.molpharmaceut.1c00781] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
SBA-15 mesoporous silica (MPS) has been widely used in oral drug delivery; however, it has not been utilized for solidifying lipid-based formulations, and the impact of their characteristic intrawall microporosity remains largely unexplored. Here, we derive the impact of the MPS microporosity on the in vitro solubilization and in vivo oral pharmacokinetics of the prostate cancer drug abiraterone acetate (AbA) when coencapsulated along with medium chain lipids into the pores. AbA in lipid (at 80% equilibrium solubility) was imbibed within a range of MPS particles (with comparable morphology and mesoporous structure but contrasting microporosity ranging from 0-247 m2/g), and their solid-state properties were characterized. Drug solubilization studies during in vitro lipolysis revealed that microporosity was the key factor in facilitating AbA solubilization by increasing the surface area available for drug-lipid diffusion. Interestingly, microporosity hindered hydrolysis of AbA to its active metabolite, abiraterone (Ab), under simulated intestinal conditions. This unique relationship between microporosity and AbA/Ab aqueous solubilization behavior was hypothesized to have significant implications on the subsequent bioavailability of the active metabolite. In vivo oral pharmacokinetics studies in male Sprague-Dawley rats revealed that MPS with moderate microporosity attained the highest relative bioavailability, while poor in vitro-in vivo correlations (IVIVC) existed between in vitro drug solubilization during lipolysis and in vivo AUC. Despite this, a reasonable IVIVC was established between the in vitro solubilization and in vivo Cmax, providing evidence for an association between silica microporosity and oral drug absorption.
Collapse
Affiliation(s)
- Ruba Almasri
- UniSA Clinical & Health Science, University of South Australia, Adelaide, South Australia 5000, Australia
| | - Hayley B Schultz
- UniSA Clinical & Health Science, University of South Australia, Adelaide, South Australia 5000, Australia
| | - Amalie Møller
- UniSA Clinical & Health Science, University of South Australia, Adelaide, South Australia 5000, Australia.,Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, 2100 Copenhagen, Denmark
| | - Kristen E Bremmell
- UniSA Clinical & Health Science, University of South Australia, Adelaide, South Australia 5000, Australia
| | | | - Paul Joyce
- UniSA Clinical & Health Science, University of South Australia, Adelaide, South Australia 5000, Australia
| | - Clive A Prestidge
- UniSA Clinical & Health Science, University of South Australia, Adelaide, South Australia 5000, Australia
| |
Collapse
|
4
|
Meola TR, Joyce P, Wignall A, Bremmell KE, Prestidge CA. Harnessing the potential of nanostructured formulations to mimic the food effect of lurasidone. Int J Pharm 2021; 608:121098. [PMID: 34534629 DOI: 10.1016/j.ijpharm.2021.121098] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2021] [Revised: 09/08/2021] [Accepted: 09/11/2021] [Indexed: 02/07/2023]
Abstract
Lurasidone is an important antipsychotic drug indicated for the treatment of schizophrenia and bipolar disorder, with an oral bioavailability of 9-19% owing to its poor aqueous solubility. Additionally, lurasidone exhibits a 2-fold positive food effect, such that patients must administer their medication with a meal, leading to significant non-compliance. The aim of this research was to evaluate the in vitro and in vivo performance of lurasidone when engineered as nanostructured systems. Specifically, a nanosuspension, nano-emulsion and silica-lipid hybrid (SLH) microparticles were formulated and the influence of composition and nanostructure on the mechanism of solubilisation was compared. Formulations were shown to enhance fasted state solubilisation levels in vitro by up to 5.9-fold, compared to pure drug. Fed- and fasted-state solubilisation profiles revealed that in contrast to the nanosuspension and nano-emulsion, lurasidone SLH mitigated the positive pharmaceutical effect of lurasidone. In vivo pharmacokinetic evaluations revealed that the nanosuspension, nano-emulsion and SLH enhanced the bioavailability of lurasidone by 3-fold, 2.4-fold and 8.8-fold, respectively, compared to pure drug after oral administration. For lurasidone, the combination of lipid-based nanostructure and porous silica nanostructure (SLH) led to optimal fasted state bioavailability which can ultimately result in enhanced treatment efficacy, easier dosing regimens and improved patient outcomes.
Collapse
Affiliation(s)
- Tahlia R Meola
- UniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia 5000, Australia; ARC Centre for Excellence in Bio-Nano Science and Technology, Adelaide, South Australia 5000, Australia
| | - Paul Joyce
- UniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia 5000, Australia; ARC Centre for Excellence in Bio-Nano Science and Technology, Adelaide, South Australia 5000, Australia
| | - Anthony Wignall
- UniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia 5000, Australia; ARC Centre for Excellence in Bio-Nano Science and Technology, Adelaide, South Australia 5000, Australia
| | - Kristen E Bremmell
- UniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia 5000, Australia; ARC Centre for Excellence in Bio-Nano Science and Technology, Adelaide, South Australia 5000, Australia
| | - Clive A Prestidge
- UniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia 5000, Australia; ARC Centre for Excellence in Bio-Nano Science and Technology, Adelaide, South Australia 5000, Australia.
| |
Collapse
|
5
|
Sumaila M, Marimuthu T, Kumar P, Choonara YE. Lipopolysaccharide Nanosystems for the Enhancement of Oral Bioavailability. AAPS PharmSciTech 2021; 22:242. [PMID: 34595578 DOI: 10.1208/s12249-021-02124-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2021] [Accepted: 08/23/2021] [Indexed: 11/30/2022] Open
Abstract
Nanosystems that incorporate both polymers and lipids have garnered attention as emerging nanotechnology approach for oral drug delivery. These hybrid systems leverage on the combined properties of polymeric and lipid-based nanocarriers while eliminating their inherent limitations. In view of the safety-related benefits of naturally occurring polymers, we have focused on systems incorporating polysaccharides and derivatives into the hybrid structure. The aim of this review is to evaluate existing biopolymers with specific focus on lipopolysaccharide hybrid systems and their advancement toward enhancing oral drug delivery. Furthermore, we shall identify future research areas that require further exploration toward achieving an optimized hybrid system for easy translation into clinical use. In this review, we have appraised formulations that combined polysaccharides/derivatives with lipids in a single nanocarrier system. These formulations were grouped into lipid-core-polysaccharide-shell systems, polysaccharide-core-lipid-shell systems, self-emulsifying lipopolysaccharide hybrid systems, and hybrid lipopolysaccharide matrix systems. In these systems, we highlighted how the polysaccharide phase enhances the oral absorption of encapsulated bioactives with regard to their function and mechanism. The various lipopolysaccharide designs presented in this review demonstrated significant improvement in pharmacokinetics of bioactives. A multitude of studies found lipopolysaccharide hybrid systems as nascent nanoplatforms for the oral delivery of challenging bioactives due to features that favor gastrointestinal absorption and bioavailability improvement. With future research already geared toward product optimization and scaling up processes, as well as detailed pharmacological and toxicology pre-clinical testing, these versatile systems will have remarkable impact in clinical application.
Collapse
|
6
|
Møller A, Schultz HB, Meola TR, Müllertz A, Prestidge CA. The Influence of Solidification on the in vitro Solubilisation of Blonanserin Loaded Supersaturated Lipid-Based Oral Formulations. Eur J Pharm Sci 2021; 157:105640. [PMID: 33189902 DOI: 10.1016/j.ejps.2020.105640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Revised: 10/12/2020] [Accepted: 11/07/2020] [Indexed: 11/30/2022]
Abstract
Supersaturated silica-lipid hybrids have previously demonstrated improved in vitro solubilisation and in vivo oral bioavailability of poorly water-soluble drugs, however were only fabricated using a single lipid (LFCS type I formulations) and were not compared to their liquid precursors. This study investigated the influence of lipid formulation classification (type I vs. type II vs. type IIIA/SNEDDS) and physical state (liquid LBF vs. solidified with silica) on the in vitro solubilisation of the poorly soluble, weak base, anti-psychotic drug, blonanserin (BLON), from a supersaturated lipid-based formulation (LBF). Stable liquid supersaturated LBF were fabricated using BLON (loaded at 150% of its equilibrium solubility), and solidified through encapsulation within porous silica microparticles at a 1:1 ratio. Their physicochemical properties and in vitro solubilisation during lipolysis were compared. Supersaturated BLON was encapsulated in the non-crystalline form. All supersaturated LBF improved the solubilisation of pure BLON during lipolysis regardless of their lipid formulation type or their physical state (1.7- to 13.4-fold). SNEDDS achieved greater solubilisation than the type II formulations (1.4- to 1.7-fold). Furthermore, the liquid precursors achieved greater solubilisation than the silica solidified formulations (4.5- to 5.7-fold). Additionally, in an attempt to increase BLON solubilisation, a spray-dried SNEDDS and dual-loaded solidified super-SNEDDS solidified with silica pre-loaded with BLON was developed, however did not significantly improve solubilisation. Liquid SNEDDS were identified as the optimal oral supersaturated LBF strategy for BLON based on in vitro lipolysis studies. Solidification of LBF using silica is a viable strategy for improving stability, however for drugs such as BLON, solidification may impede in vitro release and solubilisation.
Collapse
Affiliation(s)
- Amalie Møller
- Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, 2100 Copenhagen, Denmark; UniSA: Clinical & Health Sciences, University of South Australia, Adelaide, South Australia 5000, Australia
| | - Hayley B Schultz
- UniSA: Clinical & Health Sciences, University of South Australia, Adelaide, South Australia 5000, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Mawson Lakes Campus, Mawson Lakes 5095, Australia
| | - Tahlia R Meola
- UniSA: Clinical & Health Sciences, University of South Australia, Adelaide, South Australia 5000, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Mawson Lakes Campus, Mawson Lakes 5095, Australia
| | - Anette Müllertz
- Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, 2100 Copenhagen, Denmark; Bioneer:FARMA, Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, 2100 Copenhagen, Denmark
| | - Clive A Prestidge
- UniSA: Clinical & Health Sciences, University of South Australia, Adelaide, South Australia 5000, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Mawson Lakes Campus, Mawson Lakes 5095, Australia.
| |
Collapse
|
7
|
Joyce P, Dening TJ, Meola TR, Wignall A, Ulmefors H, Kovalainen M, Prestidge CA. Contrasting Anti-obesity Effects of Smectite Clays and Mesoporous Silica in Sprague-Dawley Rats. ACS APPLIED BIO MATERIALS 2020; 3:7779-7788. [PMID: 35019518 DOI: 10.1021/acsabm.0c00969] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Porous colloids have been shown to exert unique bioactivities for mediating lipid (fat) metabolism and thereby offer significant potential as anti-obesity therapies. In this study, we compare the capacity for two classes of colloids, that is, smectite clays (Laponite XLG, LAP; montmorillonite, MMT) and mesoporous silica (SBA-15 ordered silica; MPS), to impede intestinal lipid hydrolysis and provoke lipid and carbohydrate excretion through adsorption within their particle matrices. A two-stage in vitro gastrointestinal lipolysis model revealed the capacity for both smectite clays and MPS to inhibit the rate and extent of lipase-mediated digestion under simulated fed state conditions. Each system adsorbed more than its own weight of organic media (i.e., lipid and carbohydrates) after 60 min lipolysis, with MMT adsorbing >10% of all available organics through the indiscriminate adsorption of fatty acids and glycerides. When co-administered with a high-fat diet (HFD) to Sprague-Dawley rats, treatment with MMT and MPS significantly reduced normalized rodent weight gain compared to a negative control, validating their potential to restrict energy intake and serve as anti-obesity therapies. However, in vitro-in vivo correlations revealed poor associations between in vitro digestion parameters and normalized weight gain, indicating that additional/alternate anti-obesity mechanisms may exist in vivo, while also highlighting the need for improved in vitro assessment methodologies. Despite this, the current findings emphasize the potential for porous colloids to restrict weight gain and promote anti-obesity effects to subjects exposed to a HFD and should therefore drive the development of next-generation food-grade biomaterials for the treatment and prevention of obesity.
Collapse
Affiliation(s)
- Paul Joyce
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide 5000, South Australia, Australia.,ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Adelaide 5000, South Australia, Australia
| | - Tahnee J Dening
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide 5000, South Australia, Australia.,ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Adelaide 5000, South Australia, Australia
| | - Tahlia R Meola
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide 5000, South Australia, Australia.,ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Adelaide 5000, South Australia, Australia
| | - Anthony Wignall
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide 5000, South Australia, Australia.,ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Adelaide 5000, South Australia, Australia
| | - Hanna Ulmefors
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide 5000, South Australia, Australia.,ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Adelaide 5000, South Australia, Australia
| | - Miia Kovalainen
- Research Unit of Biomedicine and Biocenter of Oulu, Faculty of Medicine, University of Oulu, P.O. Box 5000, Oulu FI-90014, Finland
| | - Clive A Prestidge
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide 5000, South Australia, Australia.,ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Adelaide 5000, South Australia, Australia
| |
Collapse
|
8
|
Whitby CP. Structuring Edible Oils With Fumed Silica Particles. FRONTIERS IN SUSTAINABLE FOOD SYSTEMS 2020. [DOI: 10.3389/fsufs.2020.585160] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
|
9
|
Meola TR, Abuhelwa AY, Joyce P, Clifton P, Prestidge CA. A safety, tolerability, and pharmacokinetic study of a novel simvastatin silica-lipid hybrid formulation in healthy male participants. Drug Deliv Transl Res 2020; 11:1261-1272. [PMID: 32918160 DOI: 10.1007/s13346-020-00853-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/07/2020] [Indexed: 01/23/2023]
Abstract
Simvastatin (SIM) is a commonly used cholesterol-lowering drug that can reduce the risk of major cardiovascular events. However, due to its poor intrinsic water solubility, the drug is poorly absorbed from the gastrointestinal tract and exhibits a low oral bioavailability of approximately 5%. The aim of this study was to fabricate and optimize SIM encapsulated silica-lipid hybrids (SLH) as a solid-state lipid-based formulation to enhance absorption and bioavailability during a human in vivo pharmacokinetic study. SLH formulations were formulated by spray drying a submicron emulsion with either Aerosil® 300 fumed silica nanoparticles (SLH-A) or Syloid® 244 amorphous micronized silica (SLH-B). A cross-over, double-blinded study design was implemented to evaluate the performance of SLH formulations compared with a commercially available formulation in 12 healthy male participants after oral administration under fasting conditions. SLH formulations enhanced the bioavailability of SIM up to 1.6-fold and more importantly the active simvastatin acid (SIMA), 3.5-fold when compared with an equivalent dose of commercial formulation. The results demonstrate that the porous nanostructure of SLH impact systemic SIM and SIMA concentrations and may serve as a novel approach to enhance the bioavailability of specifically the parent or metabolite. No significant difference was observed in exposure when SLH formulations were administered at 10 mg in comparison with 20 mg of the commercial formulation, suggesting the potential for dose reduction. The study indicated that SLH formulations were safe and well-tolerated when administered to healthy males, confirming the commercial potential of SLH to enhance the bioavailability of poorly water-soluble drugs. Graphical abstract.
Collapse
Affiliation(s)
- Tahlia R Meola
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide, South Australia, 5000, Australia
- ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, University of South Australia, Adelaide, South Australia, 5000, Australia
| | - Ahmad Y Abuhelwa
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide, South Australia, 5000, Australia
- Discipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, 5042, Australia
| | - Paul Joyce
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide, South Australia, 5000, Australia
- ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, University of South Australia, Adelaide, South Australia, 5000, Australia
| | - Peter Clifton
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide, South Australia, 5000, Australia
| | - Clive A Prestidge
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide, South Australia, 5000, Australia.
- ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, University of South Australia, Adelaide, South Australia, 5000, Australia.
| |
Collapse
|
10
|
Koroleva M, Yurtov E. Pickering emulsions stabilized with magnetite, gold, and silica nanoparticles: Mathematical modeling and experimental study. Colloids Surf A Physicochem Eng Asp 2020. [DOI: 10.1016/j.colsurfa.2020.125001] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
11
|
Almasri R, Joyce P, Schultz HB, Thomas N, Bremmell KE, Prestidge CA. Porous Nanostructure, Lipid Composition, and Degree of Drug Supersaturation Modulate In Vitro Fenofibrate Solubilization in Silica-Lipid Hybrids. Pharmaceutics 2020; 12:pharmaceutics12070687. [PMID: 32708197 PMCID: PMC7408050 DOI: 10.3390/pharmaceutics12070687] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2020] [Revised: 07/20/2020] [Accepted: 07/20/2020] [Indexed: 01/08/2023] Open
Abstract
The unique nanostructured matrix obtained by silica-lipid hybrids (SLHs) is well known to improve the dissolution, absorption, and bioavailability of poorly water-soluble drugs (PWSDs). The aim of this study was to investigate the impact of: (i) drug load: 3–22.7% w/w, (ii) lipid type: medium-chain triglyceride (Captex 300) and mono and diester of caprylic acid (Capmul PG8), and (iii) silica nanostructure: spray dried fumed silica (FS) and mesoporous silica (MPS), on the in vitro dissolution, solubilization, and solid-state stability of the model drug fenofibrate (FEN). Greater FEN crystallinity was detected at higher drug loads and within the MPS formulations. Furthermore, an increased rate and extent of dissolution was achieved by FS formulations when compared to crystalline FEN (5–10-fold), a commercial product; APO-fenofibrate (2.4–4-fold) and corresponding MPS formulations (2–4-fold). Precipitation of FEN during in vitro lipolysis restricted data interpretation, however a synergistic effect between MPS and Captex 300 in enhancing FEN aqueous solubilization was attained. It was concluded that a balance between in vitro performance and drug loading is key, and the optimum drug load was determined to be between 7–16% w/w, which corresponds to (200–400% equilibrium solubility in lipid Seq). This study provides valuable insight into the impact of key characteristics of SLHs, in constructing optimized solid-state lipid-based formulations for the oral delivery of PWSDs.
Collapse
Affiliation(s)
- Ruba Almasri
- UniSA Clinical and Health Sciences, University of South Australia, Adelaide 5000, Australia; (R.A.); (P.J.); (H.B.S.); (N.T.); (K.E.B.)
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Adelaide 5000, Australia
| | - Paul Joyce
- UniSA Clinical and Health Sciences, University of South Australia, Adelaide 5000, Australia; (R.A.); (P.J.); (H.B.S.); (N.T.); (K.E.B.)
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Adelaide 5000, Australia
| | - Hayley B. Schultz
- UniSA Clinical and Health Sciences, University of South Australia, Adelaide 5000, Australia; (R.A.); (P.J.); (H.B.S.); (N.T.); (K.E.B.)
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Adelaide 5000, Australia
| | - Nicky Thomas
- UniSA Clinical and Health Sciences, University of South Australia, Adelaide 5000, Australia; (R.A.); (P.J.); (H.B.S.); (N.T.); (K.E.B.)
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Adelaide 5000, Australia
| | - Kristen E. Bremmell
- UniSA Clinical and Health Sciences, University of South Australia, Adelaide 5000, Australia; (R.A.); (P.J.); (H.B.S.); (N.T.); (K.E.B.)
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Adelaide 5000, Australia
| | - Clive A. Prestidge
- UniSA Clinical and Health Sciences, University of South Australia, Adelaide 5000, Australia; (R.A.); (P.J.); (H.B.S.); (N.T.); (K.E.B.)
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Adelaide 5000, Australia
- Correspondence: ; Tel.: +61-8830-22438
| |
Collapse
|
12
|
Meola TR, Paxton K, Joyce P, Schultz HB, Prestidge CA. The effect of drug ionization on lipid-based formulations for the oral delivery of anti-psychotics. ADMET AND DMPK 2020; 8:437-451. [PMID: 35300191 PMCID: PMC8915591 DOI: 10.5599/admet.830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2020] [Revised: 07/15/2020] [Indexed: 11/18/2022] Open
Abstract
Lipid-based formulations (LBFs) are well-known to improve the oral bioavailability of poorly water-soluble drugs (PWSDs) by presenting the drug to the gastrointestinal environment in a molecularly dispersed state, thus avoiding the rate-limiting dissolution step. Risperidone and lurasidone are antipsychotics drugs which experience erratic and variable absorption, leading to a low oral bioavailability. The aim of this research was to develop and investigate the performance of risperidone and lurasidone when formulated as an emulsion and silica-lipid hybrid (SLH). Lurasidone and risperidone were dissolved in Capmul® MCM at 100% and 80% their equilibrium solubility, respectively, prior to forming a sub-micron emulsion. SLH microparticles were fabricated by spray-drying a silica stabilised sub-micron emulsion to form a solid powder. The performances of the formulations were evaluated in simulated intestinal media under digesting conditions, where the emulsion and SLH provided a 17-fold and 23-fold increase in LUR solubilisation, respectively. However, the performance of RIS was reduced by 2.2-fold when encapsulated within SLH compared to pure drug. Owing to its pKa, RIS adsorbed to the silica and thus, dissolution was significantly hindered. The results reveal that LBFs may not overcome the challenges of all PWSDs and physiochemical properties must be carefully considered when predicting drug performance.
Collapse
Affiliation(s)
- Tahlia R Meola
- UniSA: Clinical and Health Sciences, University of South Australia, City West Campus, Adelaide, South Australia 5000, Australia.,ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, University of South Australia, City West Campus, Adelaide, South Australia 5000, Australia
| | - Kara Paxton
- UniSA: Clinical and Health Sciences, University of South Australia, City West Campus, Adelaide, South Australia 5000, Australia.,ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, University of South Australia, City West Campus, Adelaide, South Australia 5000, Australia
| | - Paul Joyce
- UniSA: Clinical and Health Sciences, University of South Australia, City West Campus, Adelaide, South Australia 5000, Australia.,ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, University of South Australia, City West Campus, Adelaide, South Australia 5000, Australia
| | - Hayley B Schultz
- UniSA: Clinical and Health Sciences, University of South Australia, City West Campus, Adelaide, South Australia 5000, Australia.,ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, University of South Australia, City West Campus, Adelaide, South Australia 5000, Australia
| | - Clive A Prestidge
- UniSA: Clinical and Health Sciences, University of South Australia, City West Campus, Adelaide, South Australia 5000, Australia.,ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, University of South Australia, City West Campus, Adelaide, South Australia 5000, Australia
| |
Collapse
|
13
|
Schultz HB, Wignall AD, Thomas N, Prestidge CA. Enhancement of abiraterone acetate oral bioavailability by supersaturated-silica lipid hybrids. Int J Pharm 2020; 582:119264. [PMID: 32278053 DOI: 10.1016/j.ijpharm.2020.119264] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2020] [Revised: 03/05/2020] [Accepted: 03/23/2020] [Indexed: 12/28/2022]
Abstract
Abiraterone acetate (AbA) has an oral bioavailability of <10% due to its poor water solubility. Here we investigate the performance of silica-lipid hybrids (SLH) and supersaturated SLH (super-SLH) in improving oral bioavailability of AbA. Specifically, we investigate the influence of lipid type and AbA saturation level of the equilibrium solubility in the lipid (Seq), and explore in vitro-in vivo correlation (IVIVC). An oral pharmacokinetic study was conducted in fasted Sprague-Dawley rats. Suspensions of the formulations were administered via oral gavage at an AbA dose of 25 mg/kg. Plasma samples were collected and analyzed for drug content. SLH with a saturation level of 90% Seq enhanced the oral bioavailability of unformulated AbA by 31-fold, and super-SLH with saturation levels of 150, 200 and 250% Seq, enhanced the bioavailability by 11, 10 and 7-fold, respectively. In comparison with the commercial product Zytiga, SLH (90% Seq) increased the oral bioavailability 1.43-fold whereas super-SLH showed no improvement. A reasonable IVIVC existed between the performance of unformulated AbA, SLH and super-SLH, in the in vitro lipolysis and in vivo oral pharmacokinetic studies. SLH and super-SLH significantly enhanced the oral bioavailability of AbA. Additionally, supersaturation of SLH improved drug loading but did not correlate with enhanced AbA bioavailability.
Collapse
Affiliation(s)
- Hayley B Schultz
- University of South Australia Cancer Research Institute, Adelaide, South Australia 5000, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Mawson Lakes Campus, Mawson Lakes 5095, Australia
| | - Anthony D Wignall
- University of South Australia Cancer Research Institute, Adelaide, South Australia 5000, Australia
| | - Nicky Thomas
- University of South Australia Cancer Research Institute, Adelaide, South Australia 5000, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Mawson Lakes Campus, Mawson Lakes 5095, Australia
| | - Clive A Prestidge
- University of South Australia Cancer Research Institute, Adelaide, South Australia 5000, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Mawson Lakes Campus, Mawson Lakes 5095, Australia.
| |
Collapse
|
14
|
Meola TR, Schultz HB, Peressin KF, Prestidge CA. Enhancing the oral bioavailability of simvastatin with silica-lipid hybrid particles: The effect of supersaturation and silica geometry. Eur J Pharm Sci 2020; 150:105357. [PMID: 32446169 DOI: 10.1016/j.ejps.2020.105357] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2020] [Revised: 04/16/2020] [Accepted: 04/20/2020] [Indexed: 01/01/2023]
Abstract
Silica-lipid hybrid (SLH) microparticles are a solidified lipid-based drug delivery system under investigation for their aptitude to enhance the oral bioavailability of poorly water-soluble drugs. The cholesterol-lowering agent, simvastatin (SIM), is poorly water-soluble and undergoes extensive first pass metabolism, resulting in a low oral bioavailability of approximately 5%. Hence, the current pre-clinical studies investigated the application of SLH technology to SIM with a supersaturation approach, aiming to enhance bioavailability and drug loading capacity. Additionally, the effect of silica was explored by evaluating the performance of SLH fabricated with silica of different particle geometries. SLH microparticles with supersaturated SIM loading levels ranging from 100% to 400% above the equilibrium solubility were successfully fabricated using either Aerosil® 300 or Syloid® 244 silica. All SLH formulations existed as white free-flowing powders, consisting of spherical porous microparticles for Aerosil® 300, and aggregated irregular microparticles for Syloid® 244. During in vitro dissolution in pH 7.0 media, the SLH formulations performed up to 4.4-fold greater than pure SIM powder. Furthermore, in vivo oral pharmacokinetics in male Sprague-Dawley rats revealed that the SLH formulations enhanced the oral bioavailability of SIM up to 6.1-fold and 2.9-fold, in comparison to pure SIM powder and a commercially available formulation (Simvastatin Sandoz®), respectively. The greatest in vivo performance enhancement was observed for the SLH formulation manufactured with Syloid® 244 silica with a supersaturation level of 200%. SLH technology demonstrated to be a successful formulation strategy to significantly improve the oral bioavailability of SIM in rodents and therefore, has a strong potential to also improve the oral bioavailability of SIM in humans.
Collapse
Affiliation(s)
- Tahlia R Meola
- University of South Australia, Clinical and Health Sciences, Adelaide, South Australia 5000, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, University of South Australia, City West Campus, Adelaide, South Australia 5000, Australia
| | - Hayley B Schultz
- University of South Australia, Clinical and Health Sciences, Adelaide, South Australia 5000, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, University of South Australia, City West Campus, Adelaide, South Australia 5000, Australia
| | - Karl F Peressin
- University of South Australia, Clinical and Health Sciences, Adelaide, South Australia 5000, Australia
| | - Clive A Prestidge
- University of South Australia, Clinical and Health Sciences, Adelaide, South Australia 5000, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, University of South Australia, City West Campus, Adelaide, South Australia 5000, Australia.
| |
Collapse
|
15
|
Joyce P, Ulmefors H, Garcia-Bennett A, Prestidge CA. Microporosity, Pore Size, and Diffusional Path Length Modulate Lipolysis Kinetics of Triglycerides Adsorbed onto SBA-15 Mesoporous Silica Particles. LANGMUIR : THE ACS JOURNAL OF SURFACES AND COLLOIDS 2020; 36:3367-3376. [PMID: 32167765 DOI: 10.1021/acs.langmuir.0c00253] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Understanding lipase-mediated hydrolysis mechanisms within solid-state nanocarriers is fundamental for the rational design of lipid-based formulations. In this study, SBA-15 ordered mesoporous silica (MPS) particles were engineered with well-controlled nanostructural properties to systematically elucidate the role of intrawall microporosity, mesopore size, and particle structure on lipase activity. The microporosity and diffusional path length were shown to be key modulators for lipase-provoked hydrolysis of medium chain triglycerides confined within MPS, with small changes in the pore size, between 9 and 13 nm, showing now a clear correlation to lipase activity. Lipid speciation within MPS after lipolysis, obtained through 1H NMR, indicated that free fatty acids preferentially adsorbed to rod-shaped MPS (RodMPS) particles with high microporosity. MPS that formed aggregated spindle-like structures (AggMPS) had intrinsically reduced microporosity, which was hypothesized to limit lipase/lipid diffusion to and from the MPS pores and thus retard lipolysis kinetics. A linear correlation between the microporosity and the extent of lipase-provoked hydrolysis was observed within both AggMPS and RodMPS, ultimately indicating that the intricate interplay between the microporosity and lipid/lipase diffusion can be harnessed to optimize lipolysis kinetics for silica-lipid hybrid carriers. The new insights derived in this study are integral to the future development of solid-state lipid-based nanocarriers that control the lipase activity for improving the absorption of poorly soluble bio-active compounds.
Collapse
Affiliation(s)
- Paul Joyce
- School of Pharmacy and Medical Sciences, University of South Australia, City East Campus, Adelaide, South Australia 5000, Australia
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Adelaide 5000, Australia
| | - Hanna Ulmefors
- School of Pharmacy and Medical Sciences, University of South Australia, City East Campus, Adelaide, South Australia 5000, Australia
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Adelaide 5000, Australia
| | | | - Clive A Prestidge
- School of Pharmacy and Medical Sciences, University of South Australia, City East Campus, Adelaide, South Australia 5000, Australia
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Adelaide 5000, Australia
| |
Collapse
|
16
|
Maghrebi S, Prestidge CA, Joyce P. An update on polymer-lipid hybrid systems for improving oral drug delivery. Expert Opin Drug Deliv 2019; 16:507-524. [PMID: 30957577 DOI: 10.1080/17425247.2019.1605353] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
INTRODUCTION A promising approach that has recently emerged to overcome the complex biobarriers and interrelated challenges associated with oral drug absorption is to combine the benefits of polymeric and lipid-based nanocarriers within one hybrid system. This multifaceted formulation strategy has given rise to a plethora of polymer-lipid hybrid (PLH) systems with varying nanostructures and biological activities, all of which have demonstrated the ability to improve the biopharmaceutical performance of a wide range of challenging therapeutics. AREAS COVERED The multitude of polymers that can be combined with lipids to exert a synergistic effect for oral drug delivery have been identified, reviewed and critically evaluated. Specific focus is attributed to preclinical studies performed within the past 5 years that have elucidated the role and mechanism of the polymer phase in altering the oral absorption of encapsulated therapeutics. EXPERT OPINION The potential of PLH systems has been clearly identified; however, improved understanding of the structure-activity relationship between PLH systems and oral absorption is fundamental for translating this promising delivery approach into a clinically relevant formulation. Advancing research within this field to identify optimal polymer, lipid combinations and engineering conditions for specific therapeutics are therefore encouraged.
Collapse
Affiliation(s)
- Sajedehsadat Maghrebi
- a School of Pharmacy and Medical Sciences , University of South Australia , Adelaide , South Australia , Australia.,b ARC Centre of Excellence in Convergent Bio-Nano Science and Technology , University of South Australia , Adelaide , South Australia , Australia
| | - Clive A Prestidge
- a School of Pharmacy and Medical Sciences , University of South Australia , Adelaide , South Australia , Australia.,b ARC Centre of Excellence in Convergent Bio-Nano Science and Technology , University of South Australia , Adelaide , South Australia , Australia
| | - Paul Joyce
- c Department of Physics , Chalmers University of Technology , Gothenburg , Sweden
| |
Collapse
|
17
|
Joyce P, Dening TJ, Meola TR, Schultz HB, Holm R, Thomas N, Prestidge CA. Solidification to improve the biopharmaceutical performance of SEDDS: Opportunities and challenges. Adv Drug Deliv Rev 2019; 142:102-117. [PMID: 30529138 DOI: 10.1016/j.addr.2018.11.006] [Citation(s) in RCA: 62] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2018] [Revised: 11/21/2018] [Accepted: 11/27/2018] [Indexed: 01/28/2023]
Abstract
Self-emulsifying drug delivery systems (SEDDS) offer potential for overcoming the inherent slow dissolution and poor oral absorption of hydrophobic drugs by retaining them in a solubilised state during gastrointestinal transit. However, the promising biopharmaceutical benefits of liquid lipid formulations has not translated into widespread commercial success, due to their susceptibility to long term storage and in vivo precipitation issues. One strategy that has emerged to overcome such limitations, is to combine the solubilisation and dissolution enhancing properties of lipids with the stabilising effects of solid carrier materials. The development of intelligent hybrid drug formulations has presented new opportunities to harness the potential of emulsified lipids in optimising oral bioavailability for lipophilic therapeutics. Specific emphasis of this review is placed on the impact of solidification approaches and excipients on the biopharmaceutical performance of self-emulsifying lipids, with findings highlighting the key design considerations that should be implemented when developing hybrid lipid-based formulations.
Collapse
|
18
|
Schultz HB, Kovalainen M, Peressin KF, Thomas N, Prestidge CA. Supersaturated Silica-Lipid Hybrid Oral Drug Delivery Systems: Balancing Drug Loading and In Vivo Performance. J Pharmacol Exp Ther 2018; 370:742-750. [DOI: 10.1124/jpet.118.254466] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2018] [Accepted: 12/12/2018] [Indexed: 12/16/2022] Open
|